138 related articles for article (PubMed ID: 38482671)
21. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics and prognosis of resectable lung adenosquamous carcinoma: a population-based study of the SEER database.
Wang T; Zhou J; Wang Y; Zheng Q; Lin Z; Li G; Mei J; Liu L
Jpn J Clin Oncol; 2022 Oct; 52(10):1191-1200. PubMed ID: 35726160
[TBL] [Abstract][Full Text] [Related]
23. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
El Hag M; Schmidt L; Roh M; Michael CW
Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
[TBL] [Abstract][Full Text] [Related]
24. Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.
Shiran I; Heller E; Jessel S; Kamer I; Daniel-Meshulam I; Navon R; Urban D; Onn A; Bar J
Clin Lung Cancer; 2017 May; 18(3):316-323.e1. PubMed ID: 28237243
[TBL] [Abstract][Full Text] [Related]
25. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.
Zhao W; Wang H; Peng Y; Tian B; Peng L; Zhang DC
Int J Clin Exp Pathol; 2014; 7(7):4247-53. PubMed ID: 25120805
[TBL] [Abstract][Full Text] [Related]
26. Lack of imbalance between the master regulators TTF1/NKX2-1 and ΔNp63/p40 implies adverse prognosis in non-small cell lung cancer.
Vescio M; Bulloni M; Pelosi G; Pattini L
Sci Rep; 2024 Jan; 14(1):2467. PubMed ID: 38291083
[TBL] [Abstract][Full Text] [Related]
27. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
28. p40 (ΔNp63) and keratin 34βE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples.
Butnor KJ; Burchette JL
Hum Pathol; 2013 Aug; 44(8):1479-86. PubMed ID: 23528865
[TBL] [Abstract][Full Text] [Related]
29. TP53, NOTCH2, and STK11 Mutations in a Rare Tumor of non-Small Cell Lung Carcinoma with Diffuse Coexpression of TTF1 and p40 in the Same Tumor Cells.
Guo X; Dong L; Liu H; Chen X
Int J Surg Pathol; 2023 Sep; 31(6):1041-1047. PubMed ID: 36253711
[No Abstract] [Full Text] [Related]
30. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray.
Turner BM; Cagle PT; Sainz IM; Fukuoka J; Shen SS; Jagirdar J
Arch Pathol Lab Med; 2012 Feb; 136(2):163-71. PubMed ID: 22288963
[TBL] [Abstract][Full Text] [Related]
31. The adenosquamous lung carcinoma: clinical and pathological characteristics.
Hofmann HS; Knolle J; Neef H
J Cardiovasc Surg (Torino); 1994 Dec; 35(6):543-7. PubMed ID: 7698972
[TBL] [Abstract][Full Text] [Related]
32. Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
Koyi H; Brandén E; Kasim I; Wilander E
Anticancer Res; 2018 Jun; 38(6):3341-3346. PubMed ID: 29848682
[TBL] [Abstract][Full Text] [Related]
33. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
Ito R; Iwano S; Kishimoto M; Ito S; Kato K; Naganawa S
Ann Nucl Med; 2015 Dec; 29(10):897-905. PubMed ID: 26342592
[TBL] [Abstract][Full Text] [Related]
34. Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.
Savari O; Febres-Aldana C; Chang JC; Fanaroff RE; Ventura K; Bodd F; Paik P; Vundavalli M; Saqi A; Askin FB; Travis WD; Rekhtman N
Histopathology; 2023 Jan; 82(2):242-253. PubMed ID: 36130728
[TBL] [Abstract][Full Text] [Related]
35. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
36. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
37. Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy.
Albero-González R; Munné-Collado J; Pijuan L; Simón M; Gimeno-Beltrán J; Mojal S; Salido M; Clavé S; Juanpere N; Dalmases A; Comerma L; Vázquez I; Sánchez-Font A; Taus Á; Hernández S; Lloveras B; Lloreta Trull J
Ultrastruct Pathol; 2019; 43(6):237-247. PubMed ID: 31810413
[TBL] [Abstract][Full Text] [Related]
38. p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63.
Nobre AR; Albergaria A; Schmitt F
Acta Cytol; 2013; 57(1):1-8. PubMed ID: 23221041
[TBL] [Abstract][Full Text] [Related]
39. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
40. CDX-2 Expression in Primary Lung Adenocarcinoma.
Cowan ML; Li QK; Illei PB
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
